HC Wainwright Reiterates “Buy” Rating for Cardiol Therapeutics (TSE:CRDL)

HC Wainwright restated their buy rating on shares of Cardiol Therapeutics (TSE:CRDL) in a research report report published on Monday, BayStreet.CA reports.

Cardiol Therapeutics Price Performance

Shares of CRDL stock opened at C$2.50 on Monday. Cardiol Therapeutics has a 1 year low of C$0.74 and a 1 year high of C$2.94. The firm’s 50 day moving average is C$2.31 and its 200-day moving average is C$1.63. The firm has a market capitalization of C$162.78 million, a price-to-earnings ratio of -5.81 and a beta of 0.75. The company has a current ratio of 5.29, a quick ratio of 6.84 and a debt-to-equity ratio of 0.52.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.